Lucy Scientific terminates Bluesky Biologicals amalgamation agreement due to missing audited financials

Lucy Scientific Discovery, Inc.

Terminated Amalgamation Agreement with Bluesky Biologicals on March 5, 2024, per Article 6.1.
Reason: Bluesky failed to timely provide audited financial statements, as required under the agreement.
Original agreement dated September 12, 2023, for a three-cornered amalgamation involving Lucy issuing securities.
Either party could terminate if conditions not met by December 31, 2023; Lucy exercised that right.

item 1.02

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lucy Scientific Discovery, Inc. terminated Amalgamation Agreement with Bluesky Biologicals Inc. (effective 2024-03-05).

Action: termination
Agreement: merger
Counterparty: Bluesky Biologicals Inc.
Effective: 2024-03-05

Exact text from the filing

nd Bluesky Biologicals Inc., a corporation existing under the laws of the Province of British Columbia (“ Bluesky ” or “ Acquiree ”), entered into that certain Amalgamation Agreement (the “ Agreement ”), pursuant to

View on SEC.gov

565 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001213900-24-021841

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.